
FDA Unveils New Biosimilar Approval Plan to Cut Drug Costs and Boost Competition in the U.S.
FDA Accelerates Biosimilar Approvals to Lower Prescription Costs The U.S. Food and Drug Administration (FDA) has introduced a new framework designed to simplify and speed up the approval process for biosimilar drugs — generic versions of complex biological medicines used to treat conditions such as cancer, autoimmune disorders, and rare











